Swiss law would weaken wildlife protection

Science ◽  
2020 ◽  
Vol 369 (6511) ◽  
pp. 1576.2-1576
Author(s):  
Raphaël Arlettaz ◽  
Guillaume Chapron

2021 ◽  
Vol 2 (1) ◽  
pp. 40-47
Author(s):  
Yangjian Zhang ◽  
Ran Zhao ◽  
Yaojie Liu ◽  
Ke Huang ◽  
Juntao Zhu


Oryx ◽  
1967 ◽  
Vol 9 (3) ◽  
pp. 196-210 ◽  
Author(s):  
R. A. Hibbert

Although the Mongolian People's Republic, last refuge of the Przewalski wild horse, is one of the most thinly populated countries in the world, the wildlife decreased considerably in the 30's and 40's. There has been some improvement in recent years, and the Game Law now gives protection to nearly all mammals—the few exceptions include the wolf, understandably in a country with vast herds of domestic animals. Mr. Hibbert, who was British Chargé d'Affaires at Ulan Bator from 1964 to 1966, and has since spent a year at Leeds University working on Mongolian materials, assesses the status of the major species of mammals, birds and fish, and describes the game laws.



2008 ◽  
Vol 3 (1) ◽  
pp. 25-40 ◽  
Author(s):  
Annu Jalais

The global 'cosmopolitan' tiger, as opposed to the local 'Sundarbans tiger', has become the rallying point for urbanites' concerns for wildlife protection globally. In this piece, I look at two different representations of tigers in recent history, one colonial and the other national. This so as to highlight how representations, even of wild animals, are ultimately linked to power. This leads me to argue how today's Western-dominated ideas about tigers (a view I call 'cosmopolitan') ultimately act to the detriment of 'other' tigers because these do not allow for an engagement with alternative ways of understanding animals and wildlife. Such images, I try to show using Descola's arguments about nature and understandings of it, in turn perpetrates the coercive and unequal relationship between, in this case, those who partake of the 'cosmopolitan' tiger view versus those who live with 'wild' tigers.



Author(s):  
John Sajan ◽  
B. M. Praveen Kumar ◽  
K. Sivakumar ◽  
B. C. Choudhury


2021 ◽  
Vol 47 (3) ◽  
pp. 493-496
Author(s):  
Sachin Sharma ◽  
Suman Bhowmik ◽  
Laishram Ricky Meitei ◽  
Atanu Bora

The Hedge Cupid butterfly, Bothrinia chennellii (de Nicéville, 1884) (Lepidoptera: Lycaenidae) is rediscovered to Meghalaya, India, from two different localities since its last known records. The species was last recorded 63 years ago by Cantlie from Shillong, Khasi Hills, Meghalaya in 1952 and since then no records of this species has been found in the literature of the state. The species is legally protected under Schedule II of the Indian Wildlife (Protection) Act, 1972. In this paper taxonomy, distribution and current habitat of the species are discussed.



2019 ◽  
Vol 2 (3) ◽  
pp. 58
Author(s):  
Sıtkı Anlam Altay

Turkish Joint Stock Corporations Law is based upon Swiss Law. Turkish Commercial Code of 2012 reflects a pure reception of the rules regarding the representation of the company from Swiss Law. However in 2014, Turkish Law has confronted the enforcement of Art. 371/7 TCC, which enables restrictions on the representation authority in terms of the material and monetary scope of the transaction. This study aims to bring a critical view of this regulation and to introduce a draft for a well-directed regulation with respect to restrictions related to power of representation.



2008 ◽  
Vol 15 (2) ◽  
pp. 183-195
Author(s):  
Valerie Junod

AbstractMedical research on minors entails both risks and benefits. Under Swiss law, clinical trials on children, including nontherapeutic drug trials, are permissible. However, ethics committees must systematically verify that all clinical studies have a favorable risk-benefit profile. Additional safeguards are designed to ensure that children are not unnecessarily involved in research and that proper consent is always obtained. Federal Swiss law is undergoing revision to extend these protections beyond clinical trials to a broad array of health research. The Swiss drug agency also seeks to improve the incentives for pharmaceutical firms to develop new paediatric drugs and relevant paediatric drug labels.



Sign in / Sign up

Export Citation Format

Share Document